Coartem Shortage: What Providers and Prescribers Need to Know in 2026

Coartem Shortage: What Providers and Prescribers Need to Know in 2026

If you're prescribing Coartem (Artemether/Lumefantrine) for your patients, you've likely encountered the disconnect: Coartem is FDA-approved, it's a first-line antimalarial, and yet patients routinely report they can't find it at their pharmacy. This briefing covers the current availability landscape, prescribing implications, cost considerations, and practical resources to help your patients access treatment.

Current Shortage Status and Timeline

As of 2026, Coartem is not listed on the FDA Drug Shortage database. There is no formal manufacturing or supply chain disruption affecting Coartem production by Novartis.

However, the practical reality for patients is that Coartem is functionally difficult to obtain at most US retail pharmacies. This has been a persistent pattern since the drug's FDA approval in April 2009, driven by the fundamental economics of antimalarial distribution in a non-endemic country.

Key timeline points:

• April 2009: FDA approval of Coartem for acute, uncomplicated P. falciparum malaria
• 2009–present: No FDA-approved generic has entered the US market
• 2024–2026: US drug shortage crisis affects 300+ medications, but Coartem's availability challenges remain distinct from the broader shortage landscape — driven by low demand rather than manufacturing issues

Prescribing Implications

When to Prescribe Coartem

Per CDC guidelines, Artemether/Lumefantrine (Coartem) is a first-line treatment for:

• Acute, uncomplicated P. falciparum malaria (including chloroquine-resistant strains)
• Uncomplicated malaria due to P. vivax, P. ovale, P. malariae, or P. knowlesi (though species-specific treatments may be preferred)

Coartem is not approved for:

• Severe or complicated malaria (IV artesunate is first-line)
• Malaria prophylaxis/prevention

Dosing Summary

Adults (≥35 kg): 4 tablets (20 mg Artemether/120 mg Lumefantrine each) per dose, 6 doses over 3 days = 24 tablets total.

Pediatric dosing is weight-based:

• 5 to <15 kg: 1 tablet per dose
• 15 to <25 kg: 2 tablets per dose
• 25 to <35 kg: 3 tablets per dose

All doses should be taken with food (fatty food improves bioavailability significantly). The schedule: initial dose → 8 hours later → then twice daily for 2 more days.

Key Drug Interaction Considerations

Before prescribing Coartem, review the patient's medication list for:

• QT-prolonging agents: Class IA/III antiarrhythmics (Quinidine, Amiodarone, Sotalol), antipsychotics (Pimozide, Ziprasidone), macrolide antibiotics, fluoroquinolones
• Strong CYP3A4 inducers (contraindicated): Rifampin, Carbamazepine, Phenytoin, St. John's Wort — these reduce Coartem levels and may cause treatment failure
• CYP3A4 inhibitors: Ketoconazole, HIV protease inhibitors, Erythromycin — these increase Lumefantrine exposure and QT risk
• CYP2D6 substrates: Coartem inhibits CYP2D6; exercise caution with Flecainide, Metoprolol, tricyclic antidepressants

For a comprehensive interaction reference, see our guide on Coartem drug interactions.

Availability Picture

The practical availability challenge breaks down as follows:

Where Coartem IS Likely Available

• Hospital outpatient pharmacies (especially academic medical centers)
• Pharmacies affiliated with infectious disease or travel medicine clinics
• Specialty pharmacies focused on infectious disease
• Large urban pharmacies in metropolitan areas with high international travel volumes

Where Coartem IS NOT Likely Available

• Standard retail chain pharmacies (CVS, Walgreens, Rite Aid)
• Rural or suburban pharmacies
• Mail-order pharmacies (turnaround time incompatible with urgent malaria treatment)

Why This Matters Clinically

Malaria treatment is time-sensitive. CDC guidelines emphasize initiating treatment as soon as possible after diagnosis. If you prescribe Coartem and the patient's pharmacy doesn't carry it, the resulting delay could worsen outcomes — particularly for P. falciparum, which can progress to severe malaria rapidly.

Recommendation: Before sending a Coartem prescription, confirm the receiving pharmacy has it in stock, or direct the prescription to a pharmacy known to carry antimalarials.

Cost and Access Considerations

Understanding the cost landscape helps you set appropriate expectations with patients:

• Cash price: $140–$280 for a 24-tablet course (varies by pharmacy)
• No generic available: There is no FDA-approved generic Artemether/Lumefantrine in the US
• Insurance: Coverage varies; prior authorization may be required. Some plans may cover it under specialty tier
• Discount cards: SingleCare and GoodRx may reduce out-of-pocket to approximately $140–$176
• Patient assistance: Novartis Patient Assistance Foundation (NPAF) provides Coartem free to eligible uninsured patients. Phone: 1-800-277-2254, Website: pap.novartis.com

For detailed savings strategies to share with patients, see our guide on saving money on Coartem, and for a provider-focused approach, see how to help patients save money on Coartem.

Tools and Resources for Providers

Medfinder for Providers

Medfinder for Providers lets you and your staff check real-time pharmacy inventory for Coartem before sending a prescription. This eliminates the frustrating cycle where patients go to a pharmacy, are told the medication isn't in stock, and then call your office for help.

Incorporating a quick Medfinder check into your prescribing workflow for antimalarials can save significant time for both your team and your patients.

CDC Malaria Treatment Guidelines

The CDC's malaria treatment tables (available at cdc.gov/malaria) provide species-specific and region-specific treatment recommendations, including dosing for all recommended antimalarial agents.

Novartis Patient Assistance

For uninsured or underinsured patients, the Novartis Patient Assistance Foundation (pap.novartis.com) may provide Coartem at no cost. Enrollment requires a prescription and documentation of financial need.

Alternative Antimalarials

When Coartem cannot be obtained in a clinically acceptable timeframe, consider these CDC-recommended alternatives for uncomplicated P. falciparum malaria:

1. Atovaquone/Proguanil (Malarone): Generic available, widely stocked, well-tolerated. No QT prolongation concern. Often the most practical alternative.
2. Quinine Sulfate + Doxycycline/Tetracycline/Clindamycin: Generic, affordable, widely available. More complex regimen. QT prolongation risk with Quinine.
3. Mefloquine: Generic available. Neuropsychiatric side effects limit use; boxed warning. Reserve for when other options aren't available.
4. Chloroquine: Only for malaria from chloroquine-sensitive regions. Very affordable, widely available.

For a comprehensive comparison to share with patients, see alternatives to Coartem.

Looking Ahead

Several developments could change the Coartem access landscape in the coming years:

• Generic entry: While no generic Artemether/Lumefantrine has been approved in the US, global generic versions exist (manufactured under WHO prequalification). Future generic entry would expand availability and reduce cost.
• New antimalarials: The global pipeline includes novel combination therapies, though most are years from US market entry.
• Real-time inventory tools: Services like Medfinder for Providers are making it easier to route prescriptions to pharmacies with confirmed stock.

Final Thoughts

Coartem's availability challenge is a distribution problem, not a shortage problem. As a prescriber, the most impactful steps you can take are: confirm pharmacy stock before prescribing, use tools like Medfinder for Providers, familiarize your team with alternative antimalarial regimens, and connect eligible patients with the Novartis Patient Assistance Foundation.

For a practical workflow guide on helping patients access Coartem, see our companion post: How to help your patients find Coartem in stock.